Professor Moein Moghimi, PhD 
Co-Founder and Chair, Advisory Board

Dr.  Moein Moghimi, PhD. is a renowned expert in pharmaceutical nanoscience, nanomedicine and nanosafety and has published extensively in these areas. Since August 2017, Dr. Moghimi is a Professor of Pharmaceutics (School of Pharmacy) and Research Professor (Institute of Cellular Medicine) at Newcastle University (UK). Prior to this he was Professor and Chair in Pharmaceutics at the School of Medicine, Pharmacy and Health, Durham University (UK).

 

Dr. Moghimi was also formerly a Full Affiliate Member/Professor at the Department of Translational Imaging, Houston Methodist Research Institute, Houston Methodist Hospital Systems (Houston, Texas, USA) and is currently an Adjoint Professor at the Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado-Denver Medical Center (USA). In 2015, Moein was a Visiting Professor at Università Degli Studi Di Padova, Italy. Between 2008 and March 2016, he was based at the University of Copenhagen (Denmark) serving as Professor of Nanomedicine at the Department of Pharmacy, Professor of Pharmaceutical Nanotechology at the NanoScience Centre, and the Founder and Director of the multi-million Euro Centre for Pharmaceutical Nanotechnology and Nanotoxiocology (the first interdisciplinary nanomedicine research centre in Denmark). Between 2008 and 2010, he further served as the Honorary Professor of Nanomedicine at the Multidisciplinary Research Center, Shantou University (China). His earlier appointments included a Senior Lectureship position in Biopharmacy and Molecular Pharmaceutics at the School of Pharmacy, University of Brighton and The University Research Fellow in Advanced Drug Delivery Systems at the Department of Pharmaceutical Sciences, University of Nottingham.

 

Over the past two decades, Professor Moghimi has been practicing in the capacity of advisor/consultant to over 50 pharmaceutical, biotechnology, health and food industries as well as investment banks, management consultancy firms and other entrepreneurial enterprises worldwide. He is a regular invited assessor and expert evaluator in nanomedicine/nanosafety programmes for governmental bodies, research councils and private organizations (over 50 establishments in 25 countries).

Professor Moghimi’s research activities are focused on pharmaceutical nanoscience, nanomedicine and nanosafety. More specifically, Professor Moghimi has made a major contribution to design and surface engineering of nanoparticles and functional nanosystems for parenteral site-specific targeting/drug delivery and imaging modalities (splenotropic entities, lymphotropic agents, ‘phagocyte-resistant’ nanoparticles, cerebral endothelial cell specific nanoplatforms and anti-cancer nanomedicine) as well as mechanistic understanding of nanomaterial/polymer-mediated infusion reactions and cell death processes. Professor Moghimi’s interdisciplinary research has been recognized by many international awards and to date he has been able to secure over €10 million in competitive research funds as principal investigator. Furthermore, he has partnered large-scale competitive European Commission FP-7 programmes in translational nanomedicine/drug delivery, addressing Alzheimer’s disease (The NAD Project) and atherosclerosis (CosmoPHOS NANO). In 2014 the NAD project was published as success story by Horizon 2020, endorsed by the EU President and received the prestigious Best Project Award in the category of completed projects under the European Union Framework programme in the field of industrial technologies. As of 2016, Professor Moghimi has edited multiple journal issues and is an author on >200 peer-reviewed journal articles and >10 patent/disclosure applications. He has given >300 invited seminars and keynotes in more than 30 countries.

 

Following completion of secondary education at d’Overbroeck’s College Oxford (UK), Moein studied biochemistry at the University of Manchester (UK) and in 1989 earned his PhD in biochemistry from Charing Cross and Westminster Medical School (Imperial College). He then completed a four-year SERC-funded post-doctoral training programme in Advanced Drug Delivery Research at the School of Pharmaceutical Sciences (University of Nottingham, UK).

Copyright © 2020 by  S M Discovery Group. All rights reserved.